Novo Nordisk ($NVO) says it successfully finished its third Phase IIIa study for its once-weekly GLP-1 diabetes drug semaglutide, racking up a fresh set of positive efficacy and safety data. A few months ago Novo reported that semaglutide had beat out Bydureon in a head-to-head study. "We are excited about the results of SUSTAIN 2, showing superior efficacy in glycaemic control and weight loss with semaglutide administered once-weekly compared with 100 mg sitagliptin, which is consistent with the outcome seen across all SUSTAIN trials reported to date," says Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. "The results from the SUSTAIN programme thus far support that semaglutide has the potential to become the most efficacious GLP-1 product for people with type 2 diabetes." Release